文献速递慢阻肺肺栓塞与肺血管病

吸入曲前列尼尔治疗慢阻肺相关肺动脉高压:PERFECT研究结果

Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results.
PubMed 文献 · Eur Respir J · 2024-06-06

PERFECT研究评估吸入曲前列尼尔(iTRE)在慢阻肺相关肺动脉高压(PH-COPD)患者中的安全性和有效性。多中心随机双盲安慰剂对照12周交叉设计,共76例患者随机。因iTRE增加严重不良事件风险及死亡风险提示,研究提前终止,6MWD变化数值上iTRE劣于安慰剂。结论不支持iTRE作为PH-COPD可行治疗选择。

要点

  • iTRE在PH-COPD患者中增加严重不良事件风险,研究提前终止。
  • 主要终点峰值6MWD变化数值上iTRE劣于安慰剂。
  • 结果不支持吸入曲前列尼尔用于PH-COPD治疗。

核心结论

  • iTRE在PH-COPD患者中的风险-获益观察不支持继续PERFECT研究。
  • 研究结果不支持iTRE作为PH-COPD的可行治疗选择。

研究设计与样本

  • 多中心、随机(1:1)、双盲、安慰剂对照、12周交叉研究,预设并实施基于盲态期中缺失数据分析的 contingent 平行设计。
  • 共76例患者随机,原交叉设计64例, contingent 平行设计12例;66例接受iTRE,58例接受安慰剂。
  • 入组标准为PH-COPD患者,平均肺动脉压≥30 mmHg且肺血管阻力≥4 WU。
  • iTRE最大12次呼吸(72 µg)每日4次或安慰剂治疗。
  • 主要疗效终点为第12周峰值6分钟步行距离(6MWD)变化。

主要发现

  • 研究因数据与安全监察委员会建议提前终止,依据总体证据显示iTRE增加严重不良事件风险及提示死亡风险增加。
  • 6MWD变化在iTRE暴露下数值上劣于安慰剂暴露。

临床怎么用

  • 不推荐吸入曲前列尼尔用于慢阻肺相关肺动脉高压患者的治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary hypertension (PH) accompanying COPD (PH-COPD) is associated with worse outcomes than COPD alone. There are currently no approved therapies to treat PH-COPD. The PERFECT study (ClinicalTrials.gov: NCT03496623) evaluated the safety and efficacy of inhaled treprostinil (iTRE) in this patient population. METHODS: Patients with PH-COPD (mean pulmonary arterial pressure ≥30 mmHg and pulmonary vascular resistance ≥4 WU) were enrolled in a multicentre, randomised (1:1), double-blind, placebo-controlled, 12-week, crossover study. A contingent parallel design was also prespecified and implemented, based on a blinded interim analysis of missing data. Patients received treatment with iTRE up to 12 breaths (72 µg) 4 times daily or placebo. The primary efficacy end-point was change in peak 6-min walk distance (6MWD) at week 12. RESULTS: In total, 76 patients were randomised, 64 in the original crossover design and 12 in the contingent parallel design; 66 patients received iTRE and 58 received placebo. The study was terminated early at the recommendation of the data and safety monitoring committee based on the totality of evidence that iTRE increased the risk of serious adverse events and suggestive evidence of an increased risk of mortality. The change in 6MWD was numerically worse with iTRE exposure than with placebo exposure. CONCLUSIONS: The risk-benefit observations associated with iTRE in patients with PH-COPD did not support continuation of the PERFECT study. The results of this study do not support iTRE as a viable treatment option in patients with PH-COPD.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Nathan SD, Argula R, Trivieri MG, et al. Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results. Eur Respir J. 2024. PMID: 38811045. doi:10.1183/13993003.00172-2024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。